Artistic rendering of a spherical extracellular vesicle, showing its pink outer membrane, yellow lipid structures and internal components against a blue background.
An artistic rendering of an extracellular vesicle. | Credit: Jana Zárubová, Li Lab

Stem cell-derived nanoparticles modulate immune cells and help delay type 1 diabetes in mice, UCLA study finds

The experimental approach of locally delivering nanoparticles calms harmful immune activity, helping protect insulin-producing cells
By Tiare Dunlap | Nov 18, 2026 Research

Key Takeaways

  • UCLA researchers found that extracellular vesicles — tiny particles released by nearly all cells — have powerful immune-regulating effects when derived from pluripotent stem cells and can help protect insulin-producing cells in mice.
  • In a mouse model of type 1 diabetes, the extracellular vesicles delayed disease onset, particularly when delivered through an injectable gel that gradually releases them over several days.
  • The team also developed a method that increased production of these particles 3.4-fold, addressing a key challenge in developing potential therapies.

In people with type 1 diabetes, the immune system mistakenly identifies insulin-producing cells in the pancreas as foreign and attacks them, leaving the body unable to properly regulate blood sugar. While insulin therapy helps manage the disease, it does not stop the underlying immune attack.

Now, UCLA researchers have identified a potential new way to protect these cells by harnessing extracellular vesicles — tiny particles naturally released by nearly all types of cells that help them communicate with one another.

In a study published in Nature Nanotechnology, the team found that vesicles produced by certain types of stem cells can help reduce immune attacks on insulin-producing cells in the pancreas and delay the onset of diabetes in mice. The findings suggest a possible strategy for preserving insulin-producing cells before they are destroyed.

Harnessing stem cells' natural ability to regulate immunity

The research was inspired in part by a remarkable feature of pregnancy: A mother's immune system generally tolerates a developing embryo, even though it carries genetic material from the father that her immune system could recognize as foreign.

"Nature has designed something amazing," said senior author Song Li, associate dean for graduate and professional education and a professor of bioengineering at the UCLA Samueli School of Engineering and a member of the UCLA Broad Stem Cell Research Center. "If we can better understand how an embryo avoids rejection by the mother's immune system, it could be very useful for a lot of immune-related diseases."

With that idea in mind, Li's team investigated whether extracellular vesicles released by pluripotent stem cells — which share characteristics with cells found in early embryonic development — might also possess immune-regulating properties.

The researchers compared vesicles from embryonic stem cells and induced pluripotent stem cells, or iPSCs, with those from mesenchymal stem cells, which have been widely studied for their ability to regulate inflammation.

In experiments using mouse and human immune cells, vesicles from both types of pluripotent stem cells showed stronger anti-inflammatory effects than those from mesenchymal stem cells. They also promoted the formation of regulatory T cells, specialized immune cells that help prevent the immune system from attacking the body's own tissues.

Further analysis showed that the vesicles carry distinctive proteins, lipids and genetic material that may contribute to their immune-regulating properties, providing insight into how these naturally produced nanoparticles influence immune cells.

Protecting insulin-producing cells

To test whether these immune-regulating effects could help prevent diabetes, the researchers introduced immune cells that attack insulin-producing pancreatic cells into mice, then treated the animals with extracellular vesicles derived from iPSCs.

Because extracellular vesicles are rapidly cleared from the injection site, the team developed an injectable hydrogel that gradually releases them over several days.

The treatment was injected beneath the skin near the neck, where the vesicles could interact with immune cells in nearby lymph nodes. These immune cells could then circulate throughout the body, potentially reducing harmful immune activity in the pancreas.

The researchers found that two treatments with extracellular vesicles, either alone or delivered through the hydrogel, significantly delayed the onset of diabetes compared with untreated controls. At the end of the 90-day study, 55% of mice receiving vesicles in the hydrogel remained diabetes-free.

Mice receiving vesicles in the hydrogel also had more regulatory T cells in their lymph nodes and retained more insulin-producing pancreatic tissue than control animals.

"One thing that surprised us was that a local injection could provide protection throughout the body," said Li, who is also a member of the UCLA Health Jonsson Comprehensive Cancer Center and the California NanoSystems Institute at UCLA. "That's the beauty of this approach."

Making enough particles for future therapies

The researchers also addressed a major obstacle to developing extracellular vesicle-based treatments: producing sufficient quantities of consistent, high-quality particles.

Rather than growing stem cells on flat laboratory surfaces, the team grew them in three-dimensional clusters suspended in gently moving liquid. This approach increased vesicle production 3.4-fold per million cells while preserving important characteristics of the particles.

Side-by-side microscopy images of stem cells grown in flat, 2D culture (left) and spherical, 3D clusters suspended in liquid (right), which produced more extracellular vesicles.
Stem cells grown in 3D clusters suspended in gently moving liquid (right panel) produced significantly more extracellular vesicles than stem cells grown flat in a lab dish (left panel) | Credit: Jana Zárubová, Li Lab

Because iPSCs can multiply extensively in the laboratory, they could provide a more consistent and scalable source of therapeutic vesicles than adult stem cells, whose growth potential is more limited.

The approach remains experimental, and further studies are needed to determine whether it would be safe and effective in people.

Li envisions the greatest potential for patients in earlier stages of type 1 diabetes, when some insulin-producing cells remain functional.

"In the early stages, you still have some pancreatic cells left," Li said. "If you can regulate the immune cells, you may be able to keep the remaining cells functional."

In more advanced disease, immune regulation alone would not replace cells that have already been lost. However, the approach could potentially help prevent immune rejection of transplanted insulin-producing cells.

The team hopes to test the approach in larger animal models and investigate appropriate dosing, long-term effectiveness and whether the treatment could weaken the body's defenses against infection.

Beyond diabetes, the findings could inform research into other autoimmune diseases and strategies for protecting transplanted cells from immune rejection.

Notes

The study was a collaborative effort led by first author Jana Zárubová and including UCLA faculty Xia Yang, Louis-S. Bouchard, Peter C. Butler, Manish J. Butte and Zhen Gu, as well as Reza Ardehali of Baylor College of Medicine, Jia Fan and Tony Ye Hu of Tulane University, Xiaojun Lance Lian of Pennsylvania State University and Jianyi Zhang of the University of Alabama at Birmingham.

The research was supported by the California Institute for Regenerative Medicine, the National Institutes of Health, a UCLA Broad Stem Cell Research Center Innovation Award and Breakthrough T1D.

The therapeutic concept described in this study is covered by a patent application filed by the UCLA Technology Development Group on behalf of the Regents of the University of California, with Jana Zarubova, Mohammad Mahdi Hasani-Sadrabadi and Li listed as co-inventors. 

Bioengineering & Nanotechnology Gastrointestinal & Metabolic Diseases